Training and Practices of Cannabis Dispensary Staff

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 244-251

  Haug, Nancy A ^a,b   Kieschnick, Dustin ^a   Sottile, James E ^a   Babson, Kimberly A ^c   Vandrey, Ryan ^d   Bonn Miller, Marcel O ^c,e,f  

^a PALO ALTO UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cannabis; dispensary; marijuana; practices

Indexed keywords

CANNABIS;

ADULT; ARTICLE; CONTROLLED STUDY; E-MAIL; FEMALE; HEALTH PERSONNEL ATTITUDE; HUMAN; JOB SATISFACTION; MALE; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL STAFF; ONLINE SYSTEM; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; SOCIAL MEDIA;

EID: 85043574220     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2016.0024     Document Type: Article

References (26)

1. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370:2219-2227.
2. Bonn-Miller MO, Boden MT, Bucossi MM, et al. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40:23-30.
3. Nunberg H, Kilmer B, Pacula RL, et al. An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal. 2011;4:1-14.
4. Reinarman C, Nunberg H, Lanthier F, et al. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43:128-135.
5. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344-1364.
6. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24: 515-523.
7. Bujarski SJ, Galang JN, Short NA, et al. Cannabis use disorder treatment barriers and facilitators among veterans with PTSD. Psychol Addict Behav. 2016;30:73-81.
8. Ilgen MA, Bohnert K, Kleinberg F, et al. Characteristics of adults seeking medical marijuana certification. Drug Alcohol Depend. 2013;132:654-659.
9. Zaller N, Topletz A, Frater S, et al. Profiles of medicinal cannabis patients attending compassion centers in Rhode Island. J Psychoactive Drugs. 2015;47:18-23.
10. Cohen NL, Heinz AJ, Ilgen M, et al. Pain, Cannabis species, and Cannabis use disorders. J Stud Alcohol Drugs. 2016;77:515-520.
11. Pearce DD, Mitsouras K, Irizarry KJ. Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users. J Altern Complement Med. 2014;20:787-791.
12. Belendiuk KA, Babson KA, Vandrey R, et al. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addict Behav. 2015;50:178-181.
13. Small E. Evolution and classification of cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev. 2015;81:189-294.
14. Piomelli D, Russo EB. The Cannabis sativa versus Cannabis indica debate: an interview with Ethan Russo, MD. Cannabis Cannabinoid Res. 2016;1:44-46.
15. Loflin MJ, Babson KA, Bonn-Miller MO. Cannabinoids as therapeutic for PTSD: a review. Curr Opin Psychol. 2016; in press.
16. Morabito D, Soyster P, Ramey-Wright S, et al. A review of recent advances in the therapeutic uses of secondary cannabinoids. Curr Addict Rep. 2016;3:230-238.
17. Rosenberg EC, Tsien RW, Whalley BJ, et al. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12:747-768.
18. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-2473.
19. Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex(R)): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014;74:563-578.
20. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167-184.
21. Shafaroodi H, Samini M, Moezi L, et al. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology. 2004;47:390-400.
22. Kumar S, Rao PS, Earla R, et al. Drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol. 2015;11:343-355.
23. Friedman D, Cilio MR, Tilton N, et al. The effect of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program. American Epilepsy Society: Seattle, WA, 2014.
24. Bonn-Miller MO, Sottile JE, Padula CB, et al. Routes of cannabis consumption as a function of clinical status. College on Problems of Drug Dependence: Palm Springs, CA, 2016.
25. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav. 2014;39:1430-1433.
26. Vandrey R, Raber JC, Raber ME, et al. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491-2493.